TScan Therapeutics Reports Third Quarter 2024 Financial

TScan Therapeutics Reports Third Quarter 2024 Financial Results ...

D., Chief Executive Officer. “During the third quarter we continued to prioritize screening, enrolling, and dosing patients in the solid tumor ...

TScan Therapeutics Third Quarter 2024 Earnings - Yahoo Finance

TScan Therapeutics ( NASDAQ:TCRX ) Third Quarter 2024 Results Key Financial Results Net loss: US$29.9m (loss widened by...

TScan Therapeutics Reports Third Quarter 2024 Financial

R&D Expenses: Research and development expenses for the third quarter of 2024 were $26.3 million, compared to $22.7 million for the third ...

Investor Relations | TScan Therapeutics, Inc.

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update. Upcoming oral presentation for the ALLOHA TM Phase 1 heme ...

TScan Therapeutics Reports Q3 2024 Financial Results - TipRanks

Financially, TScan reported a decrease in revenue to $1.0 million for Q3 2024, down from $3.9 million in Q3 2023, attributed to the timing of ...

TScan Therapeutics Reports Q3 2024 Financial Results

Financially, TScan reported a decrease in revenue to $1.0 million for Q3 2024, down from $3.9 million in Q3 2023, attributed to the timing of ...

TScan Therapeutics Reports Third Quarter 2024 Financial Results ...

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update · Globe Newswire: November 12, 2024 · Longwood Fund ...

TScan Therapeutics Reports Third Quarter 2024 Financial Results ...

Upcoming oral presentation forthe ALLOHATMPhase 1 heme trialat the 66thAmerican Society of Hematology (ASH) Annual Meeting and Exposition.

Press Releases - Investor Relations | TScan Therapeutics, Inc.

Press Releases. Year. None, 2024, 2023, 2022, 2021, 2020, 2019. 12 Nov '24. TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides ...

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue ...

TScan Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.05 million for the quarter ...

Compass Therapeutics Reports 2024 Third Quarter Financial ...

Cash balance of $135 million in cash and marketable securities as of September 30, 2024, which is expected to provide cash runway into the first ...

TScan Therapeutics Reports Third Quarter 2024 Financial Results ...

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update · Actively screening, enrolling, and dosing ...

Compass Therapeutics Reports 2024 Third Quarter Financial ...

The company fully enrolled its Phase 2/3 trial of CTX-009 in biliary tract cancers, with top-line data expected by Q1 2025. Net loss was $10.5 ...

Candel Therapeutics Reports Third Quarter 2024 Financial Results ...

These decreases were partially offset by clinical development costs driven by increased manufacturing costs for CAN-2409 programs. Research and ...

TScan Therapeutics Reports First Quarter 2024 Financial Results ...

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update ; Total liabilities, $, 117,865 ; Total stockholders ...

Acrivon Therapeutics Reports Third Quarter 2024 Financial Results ...

As of September 30, 2024, the company had cash, cash equivalents and marketable securities of $202.8 million, which is expected to fund our ...

TScan Therapeutics Reports Third Quarter 2023 Financial Results ...

For the third quarter ended September 30, 2023, TScan Therapeutics reported a net loss of $23.0 million, compared to a net loss of $16.2 million ...

Acrivon Therapeutics Reports Third Quarter 2024 Financial Results ...

Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient ...

TScan Therapeutics Reports Third Quarter 2024 Financial Results ...

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update · Comments Section · Community Info Section · More ...

TScan Therapeutics Reports Third Quarter 2023 Financial Results ...

Plans to complete Phase 1 dosing and report prevention of relapse data in 2024. Solid Tumor Program: TScan remains committed to populating ...